Nuvectra Corp Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-04-20: Form 8-K; Period of report 2020-04-17; Description 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 7.01.
- 2020-03-25: Form 8-K; Period of report 2020-03-25; Description 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 7.01.
- 2020-03-16: Form 8-K; Period of report 2020-03-10; Description 8.01 Other Events; Details 8.01.
- 2020-02-13: Form 8-K; Period of report 2020-02-13; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-04-20 | 8-K | 2020-04-17 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On April 17, 2020, the Company filed with the Bankruptcy Court a monthly operating report for the month ended March 31, 2020 (the “Monthly Operating Report”). 8.01 On April 16, 2020, the Company filed a notice of continued hearing with the Bankruptcy Court setting a confirmation hearing with respect to the Plan of Liquidation of Nuvectra Corporation Under Chapter 11 of the Bankruptcy Code (the “Plan”). | nvtr20200418_8k.htm |
| 2020-03-25 | 8-K | 2020-03-25 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On March 25, 2020, the Company filed with the Bankruptcy Court a monthly operating report for the month ended February 29, 2020 (the “Monthly Operating Report”). 8.01 The Company is permanently ending its operations. | nvtr20200323_8k.htm |
| 2020-03-16 | 8-K | 2020-03-10 | 8.01 Other Events | 8.01 As previously disclosed, on November 12, 2019, Nuvectra Corporation (the “Company”) filed a voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code (the “Chapter 11 Case”) in the U.S. Bankruptcy Court for the Eastern District of Texas (the “Bankruptcy Court”). | nvtr20200313_8k.htm |
| 2020-02-13 | 8-K | 2020-02-13 | 7.01 Regulation FD Disclosure | 7.01 As previously disclosed, on November 12, 2019, Nuvectra Corporation (the “Company”) filed a voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code (the “Chapter 11 Case”) in the U.S. Bankruptcy Court for the Eastern District of Texas (the “Bankruptcy Court”). | nvtr20200212_8k.htm |
| 2020-01-31 | 8-K | 2020-01-29 | 8.01 Other Events | 8.01 As previously disclosed, on November 12, 2019, Nuvectra Corporation (the “Company”) filed a voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code (the “Chapter 11 Case”) in the U.S. Bankruptcy Court for the Eastern District of Texas (the “Bankruptcy Court”). | nvtr20200130_8k.htm |
| 2020-01-15 | 8-K | 2020-01-13 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 As previously disclosed, on November 12, 2019, Nuvectra Corporation (the “Company”) filed a voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code (the “Chapter 11 Case”) in the U.S. Bankruptcy Court for the Eastern District of Texas (the “Bankruptcy Court”). 8.01 In the Chapter 11 Case, the Company is conducting a sales process to sell the assets of the Company to one or more bidders under the supervision of the Bankruptcy Court pursuant to Section 363 of the U.S. Bankruptcy Code. | nvtr20200112_8k.htm |
| 2019-12-31 | 8-K | 2019-12-20 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 As previously disclosed, on November 12, 2019, Nuvectra Corporation (the “Company”) filed a voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code (the “Chapter 11 Case”) in the U.S. Bankruptcy Court for the Eastern District of Texas (the “Bankruptcy Court”). 8.01 On December 31, 2019, the U.S. Food and Drug Administration (the “FDA”) granted full-body magnetic resonance (MR)-conditional approval for the Company’s Algovita® spinal cord stimulation product. | nvtr20191230_8k.htm |
| 2019-11-22 | 8-K | 2019-11-19 | 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 2.05 On November 19, 2019, Nuvectra Corporation (the “Company”) began to implement a reduction in force plan that is expected to result in the termination of 89 of the Company’s employees. 5.02 Due to the streamlined function of the Board of Directors of the Company (the “Board”) in the Chapter 11 Case, Jon Tremmel, Thomas Zelibor, Christopher Chavez and Jane Song each resigned from the Board shortly following the commencement of the Chapter 11 Case. 8.01 The first meeting of creditors in the Chapter 11 Case is scheduled for December 20, 2019 at 10:30 a.m. | nvtr20191120_8k.htm |
| 2019-11-14 | 8-K | 2019-11-13 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 As previously disclosed, on November 12, 2019, Nuvectra Corporation (the “Company”) filed a voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Eastern District of Texas (the “Chapter 11 Case”). | nvtr20191114_8k.htm |
| 2019-11-13 | 8-K | 2019-11-12 | 1.03 Bankruptcy or Receivership; 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; 8.01 Other Events | 1.03 On November 12, 2019, Nuvectra Corporation (the “Company”) filed a voluntary petition (the “Bankruptcy Petition”) for reorganization under Chapter 11 of the U.S. Bankruptcy Code (the “Bankruptcy Code”) in the U.S. Bankruptcy Court for the Eastern District of Texas (the “Court”). 2.04 The filing of the Bankruptcy Petition constituted an event of default under the Company’s Loan and Security Agreement, dated as of March 18, 2016, as amended, with Oxford Finance LLC and Silicon Valley Bank (the “Loan Agreement”), resulting in the acceleration of the Company’s obligations under the Loan Agreement. 8.01 On November 12, 2019, the Company issued a press release announcing the filing of the Bankruptcy Petition. | nvtr20191112_8k.htm |
| 2019-10-18 | 8-K | 2019-10-18 | 8.01 Other Events | 8.01 On October 18, 2019, Nuvectra Corporation (the “Company”) issued a press release announcing that the Company has submitted supplementary chemical composition and biocompatibility data to the U.S. Food and Drug Administration in support of the Company’s Virtis pre-market approval application for the treatment of chronic urinary retention and symptoms of overactive bladder. | nvtr20191016_8k.htm |
| 2019-09-20 | 8-K | 2019-09-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 20, 2019, Nuvectra Corporation (“Nuvectra” or the “Company”) announced that Jennifer J. Kosharek, age 38, was appointed to the position of Executive Vice President and Chief Financial Officer, effective September 16, 2019. | nvtr20190919_8k.htm |
| 2019-08-29 | 8-K | 2019-08-26 | 2.05 Costs Associated with Exit or Disposal Activities; 8.01 Other Events | 2.05 On August 29, 2019, Nuvectra Corporation (the “Company”) announced that it is implementing a reduction in force plan that is expected to result in the termination of approximately 20% to 25% of the Company’s employees during the third quarter of 2019. 8.01 On August 26, 2019, the Company issued a press release announcing that the Company is exploring potential strategic alternatives to enhance shareholder value. | nvtr20190828_8k.htm |
| 2019-07-31 | 8-K | 2019-07-31 | 2.02 Results of Operations and Financial Condition | 2.02 On July 31, 2019, Nuvectra Corporation issued a press release regarding its financial results for the quarter ended June 30, 2019. | nvtr20190730_8k.htm |
| 2019-07-15 | 8-K | 2019-07-12 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | nvtr20190711_8k.htm |
| 2019-07-10 | 8-K/A | 2019-06-27 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 1.02 The Executive Agreement with Mr. Hanchin was terminated pursuant to, and superseded by, the Separation Agreement, except as otherwise provided therein, effective June 27, 2019. 5.02 On June 28, 2019, Nuvectra Corporation (the “Company”) announced via Form 8-K that J. Paul Hanchin had resigned from his position as President of the Company, effective June 27, 2019. | nvtr20190709_8ka.htm |
| 2019-06-28 | 8-K | 2019-06-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 27, 2019, Nuvectra Corporation (the “Company”) and J. Paul Hanchin, the President of the Company, mutually agreed to Mr. Hanchin’s separation of employment from the Company, effective as of June 27, 2019. | nvtr20190627_8k.htm |
| 2019-06-18 | 8-K | 2019-06-18 | 8.01 Other Events | 8.01 On June 18, 2019, the Company posted a presentation to its internet website located at www.nuvectramed.com that it is utilizing in connection with meetings with certain current and prospective investors and customers of the Company (the “Presentation”). | nvtr20190613_8k.htm |
| 2019-06-11 | 8-K | 2019-06-07 | 8.01 Other Events | 8.01 On June 11, 2019, Nuvectra Corporation issued a press release regarding the status of its FDA submission seeking approval for full body MR Conditional for its Algovita® spinal cord stimulation product. | nvtr20190610_8k.htm |
| 2019-05-24 | 8-K | 2019-05-23 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2019 Annual Meeting of Stockholders of Nuvectra Corporation (the “Company”) was held on May 23, 2019 (the “Annual Meeting”) at 10:00 a.m. | nvtr20190523_8k.htm |
| 2019-05-16 | 8-K | 2019-05-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On May 13, 2019, Walter Z. Berger, Chief Operating Officer and Chief Financial Officer of Nuvectra Corporation (the “Company”), announced that he intended to resign from all positions with the Company, effective May 24, 2019, to pursue another business opportunity. 8.01 On May 16, 2019, the Company issued a press release announcing the resignation of Mr. Berger from his positions as Chief Operating Officer and Chief Financial Officer, effective as of May 24, 2019, and the appointment of Ms. Kosharek as interim Chief Financial Officer. | nvtr20190515_8k.htm |
| 2019-05-01 | 8-K | 2019-05-01 | 2.02 Results of Operations and Financial Condition | 2.02 On May 1, 2019, Nuvectra Corporation issued a press release regarding its financial results for the quarter ended March 31, 2019. | nvtr20190430_8k.htm |
| 2019-04-26 | 8-K | 2019-04-22 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | nvtr20190422_8k.htm |
| 2019-03-25 | 8-K | 2019-03-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On March 21, 2019, Dr. Joseph A Miller, Jr., the Chairman of the Board of Nuvectra Corporation (the “Company”), announced that he did not intend to stand for re-election at the Company’s 2019 Annual Meeting of Stockholders and that he would retire from the Board, effective immediately. 8.01 On March 25, 2019, the Company issued a press release announcing the retirement of Dr. Miller as a board member and as the Chairman of the Board and the appointment of Ms. Song as a director and member of the Board’s Governance and Nomination Committee. | nvtr20190321_8k.htm |
| 2019-03-01 | 8-K/A | 2019-01-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 5, 2019, Nuvectra Corporation (the “Company”) filed a report on Form 8-K related to the appointment of Dr. Fred B. Parks as the Company’s new Chief Executive Officer. | nvtr20190301_8ka.htm |
| 2019-02-28 | 8-K | 2019-02-28 | 2.02 Results of Operations and Financial Condition | 2.02 On February 28, 2019, Nuvectra Corporation issued a press release regarding its financial results for the quarter and year ended December 31, 2018. | nvtr20190227_8k.htm |
| 2019-02-05 | 8-K | 2019-01-30 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 1.02 The Executive Agreement with Mr. Drees was terminated pursuant to, and superseded by, the Separation Agreement, except as otherwise provided therein, effective January 31, 2019. 5.02 Effective February 1, 2019, the Company appointed Dr. Parks, age 71, as the Company’s Chief Executive Officer. 8.01 On January 31, 2019, the Company issued a press release announcing the resignation of Mr. Drees from his positions as Chief Executive Officer and a director, the appointment of Dr. Parks as Chief Executive Officer and the appointment of Mr. Chavez as a director and member of the Board’s Compensation and Organization Committee. | nvtr20190204_8k.htm |
| 2019-01-29 | 8-K | 2019-01-29 | 8.01 Other Events | 8.01 On January 29, 2019, Nuvectra Corporation issued a press release regarding the status of its FDA submission for its Virtis Sacral Nerve Stimulation product. | nvtr20190129_8k.htm |
| 2019-01-07 | 8-K | 2018-12-31 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.02 Results of Operations and Financial Condition; 2.06 Material Impairments; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.01 The description of the completion of the sale of NeuroNexus included in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. 2.02 On January 7, 2019, the Company issued a press release regarding its preliminary unaudited fourth quarter and full year 2018 revenue. 2.06 On December 31, 2018, the Company’s management determined that the fair value of NeuroNexus, based on the sale price to Buyer, was less than the current recorded carrying value of NeuroNexus. 8.01 On January 2, 2019, the Company issued a press release announcing the sale of NeuroNexus. | nvtr20181228_8k.htm |
| 2018-12-12 | 8-K | 2018-12-10 | 8.01 Other Events | 8.01 On December 12, 2018, Nuvectra Corporation (the “Company”) issued a press release announcing receipt of full-body MR-conditional approval for the Company’s Algovita® Spinal Cord Stimulation system from its European Notified Body, TÜV SÜD. | nvtr20181211_8k.htm |
| 2018-12-03 | 8-K | 2018-11-28 | 8.01 Other Events | 8.01 On December 3, 2018, Nuvectra Corporation (the “Company”) issued a press release announcing receipt of U.S. Food and Drug Administration head-only MR-conditional approval for the Company’s Algovita® Spinal Cord Stimulation system. | nvtr20181130b_8k.htm |
| 2018-10-29 | 8-K | 2018-10-29 | 2.02 Results of Operations and Financial Condition | 2.02 On October 29, 2018, Nuvectra Corporation issued a press release regarding its financial results for the quarter ended September 30, 2018. | nvtr20181026_8k.htm |
| 2018-10-03 | 8-K | 2018-09-28 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 2.03 On September 28, 2018, the Company completed a draw on its Third Tranche Term C loan (the “Term Loan C Commitment”), in the amount of $5,000,000.00, in accordance with the terms of its and Loan and Security Agreement with each of Oxford Finance LLC, a Delaware limited liability company, and Silicon Valley Bank, a California corporation (collectively, the “Lenders”), dated as of March 18, 2016, as amended (the “Loan Agreement”). 3.02 The information regarding the Warrants included in Item 2.03 above is incorporated by reference into this Item 3.02. | nvtr20181002_8k.htm |
| 2018-09-14 | 8-K | 2018-09-14 | 8.01 Other Events | 8.01 On September 14, 2018, Nuvectra Corporation issued a press release announcing the closing of its underwritten follow-on public offering of 3,248,750 shares of its common stock at a price to the public of $21.25 per share, which included the exercise in full by the underwriters of their option to purchase 423,750 additional shares of common stock. | nvtr20180913_8k.htm |
| 2018-09-13 | 8-K | 2018-09-11 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On September 11, 2018, the Company issued a press release announcing the Offering. | nvtr20180910_8k.htm |
| 2018-08-15 | 8-K | 2018-08-15 | 8.01 Other Events | 8.01 On August 15, 2018, the Company posted a presentation to its internet website located at www.nuvectramed.com that it is utilizing in connection with meetings with certain current and prospective investors and customers of the Company (the “Presentation”). | nvtr20180814_8k.htm |
| 2018-08-07 | 8-K | 2018-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2018, Nuvectra Corporation issued a press release regarding its financial results for the quarter ended June 30, 2018. | nvtr20180803_8k.htm |
| 2018-08-02 | 8-K | 2018-07-14 | 8.01 Other Events | 8.01 On July 14, 2018, Dr. Norbert Kaula notified Nuvectra Corporation (the “Company”) that he was resigning from his position of Chief Technology Officer, effective as of August 17, 2018. | nvtr20180801_8k.htm |
| 2018-07-02 | 8-K | 2018-06-18 | 8.01 Other Events | 8.01 On July 2, 2018, Nuvectra Corporation (the “Company”) announced via press release that on June 18, 2018, it received notice from the Food & Drug Administration (the “FDA”) regarding its original pre-market approval application and its subsequent amendment to such application for its VirtisTM Sacral Neuromodulation Device (“Virtis”). | nvtr20180629_8k.htm |
| 2018-06-12 | 8-K | 2018-06-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Nuvectra Corporation (the “Company”) announced on June 7, 2018 that Ms. Jennifer Kosharek, age 37, would be appointed to the position of Vice President, Controller and Principal Accounting Officer, effective as of June 8, 2018. | nvtr20180611_8k.htm |
| 2018-05-24 | 8-K | 2018-05-23 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2018 Annual Meeting of Stockholders of Nuvectra Corporation (the “Company”) was held on May 23, 2018 (the “Annual Meeting”) at 10:00 a.m. | nvtr20180523_8k.htm |
| 2018-05-02 | 8-K | 2018-05-02 | 2.02 Results of Operations and Financial Condition | 2.02 On May 2, 2018, Nuvectra Corporation issued a press release regarding its financial results for the quarter ended March 31, 2018. | nvtr20180501_8k.htm |
| 2018-03-19 | 8-K | 2018-03-13 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | nvtr20180316_8k.htm |
| 2018-03-13 | 8-K | 2018-03-12 | 8.01 Other Events | 8.01 On March 12, 2018, the Company posted a presentation to its internet website located at www.nuvectramed.com that it is utilizing in connection with meetings with certain current and prospective investors and customers of the Company (the “Presentation”). | nvtr20180312_8k.htm |
| 2018-03-06 | 8-K | 2018-03-06 | 2.02 Results of Operations and Financial Condition | 2.02 On March 6, 2018, Nuvectra Corporation issued a press release regarding its financial results for the quarter and full year ended December 31, 2017. | nvtr20180305_8k.htm |
| 2018-02-21 | 8-K | 2018-02-16 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information regarding the Second Amendment included in Item 1.01 is incorporated by reference into this Item 2.03. 3.02 The information regarding the Oxford Warrant and the Silicon Valley Warrant included in Item 1.01 is incorporated by reference into this Item 3.02. | nvtr20180220_8k.htm |
| 2018-02-06 | 8-K | 2018-02-01 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | nvtr20180130_8k.htm |
| 2018-02-05 | 8-K | 2018-02-05 | 8.01 Other Events | 8.01 On February 5, 2018, Nuvectra Corporation issued a press release announcing the closing of its underwritten follow-on public offering of 3,248,750 shares of its common stock at a price to the public of $8.00 per share, which included the exercise in full by the underwriters of their option to purchase 423,750 additional shares of common stock. | nvtr20180205_8k.htm |
| 2018-02-02 | 8-K | 2018-02-01 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On January 31, 2018, the Company issued a press release announcing the Offering. | nvtr20180130b_8k.htm |
| 2018-01-08 | 8-K | 2018-01-08 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On January 8, 2018, Nuvectra Corporation issued a press release regarding its preliminary unaudited fourth quarter and full year 2017 revenue. 8.01 On January 8, 2018, the Company posted a presentation to its internet website located at www.nuvectramed.com that it is utilizing in connection with meetings with certain current and prospective investors, suppliers and customers of the Company (the “Presentation”). | nvtr20180105_8k.htm |
| 2017-11-30 | 8-K | 2017-11-28 | 8.01 Other Events | 8.01 On November 28, 2017, the Company conducted an audio presentation at the 29th Annual Piper Jaffray Healthcare Conference, which was also posted via webcast simultaneously to the Company’s internet website located at www.nuvectramed.com (the “Presentation”). | nvtr20171130_8k.htm |
| 2017-11-01 | 8-K | 2017-11-01 | 2.02 Results of Operations and Financial Condition | 2.02 On November 1, 2017, Nuvectra Corporation issued a press release regarding its financial results for the quarter ended September 30, 2017. | nvtr20171031_8k.htm |
| 2017-10-03 | 8-K | 2017-09-28 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 2.03 On September 28, 2017, the Company completed a draw on its Second Tranche Term B loan (the “Term Loan B Commitment”), in the amount of $12,500,000.00, in accordance with the terms of its and Loan and Security Agreement with each of Oxford Finance LLC, a Delaware limited liability company, and Silicon Valley Bank, a California corporation (collectively, the “Lenders”), dated as of March 18, 2016, as amended (the “Loan Agreement”). 3.02 The information regarding the Oxford Warrant and the Silicon Valley Warrant included in Item 2.03 above is incorporated by reference into this Item 3.02. | nvtr20171002_8k.htm |
| 2017-09-05 | 8-K | 2017-08-29 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | nvtr20170901_8k.htm |
| 2017-08-23 | 8-K | 2017-08-21 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | nvtr20170822_8k.htm |
| 2017-08-08 | 8-K | 2017-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2017, Nuvectra Corporation issued a press release regarding its financial results for the quarter ended June 30, 2017. | nvtr20170802_8k.htm |
| 2017-06-30 | 8-K | 2017-06-28 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | nvtr20170629_8k.htm |
| 2017-06-21 | 8-K | 2017-06-19 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | nvtr20170620_8k.htm |
| 2017-05-24 | 8-K | 2017-05-24 | 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.07 The 2017 Annual Meeting of Stockholders of Nuvectra Corporation (the “Company”) was held on May 23, 2017 (the “Annual Meeting”) at 10:00 a.m. 8.01 On May 24, 2017, the Company posted a presentation to its internet website located at www.nuvectramed.com that it is utilizing in connection with meetings with certain current and prospective investors, suppliers and customers of the Company (the “Presentation”). | nvtr20170523b_8k.htm |
| 2017-05-09 | 8-K | 2017-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2017, Nuvectra Corporation issued a press release regarding its financial results for the quarter ended March 31, 2017. | nvtr20170505_8k.htm |
| 2017-04-04 | 8-K | 2017-03-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | nvtr20170403_8k.htm |
| 2017-03-07 | 8-K | 2017-03-07 | 2.02 Results of Operations and Financial Condition | 2.02 On March 7, 2017, Nuvectra Corporation issued a press release regarding its financial results for the quarter and full year ended December 30, 2016. | nvtr20170306_8k.htm |
| 2017-02-14 | 8-K | 2017-02-14 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | nvtr20170213_8k.htm |
| 2017-01-17 | 8-K | 2017-01-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 13, 2017, Nuvectra Corporation (the “Company”) entered into an Executive Employment Agreement with each of Mr. Scott F. Drees, the Chief Executive Officer of the Company (the “Drees Employment Agreement”), and Mr. Walter Z. Berger, the Chief Operating Officer and Chief Financial Officer of the Company (the “Berger Employment Agreement” and together with the Drees Employment Agreement, the “Agreements”), each of which will be effective as of March 7, 2016. | nvtr20170113_8k.htm |
| 2016-12-12 | 8-K | 2016-12-09 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | nvtr20161206_8k.htm |
| 2016-11-16 | 8-K | 2016-11-16 | 8.01 Other Events | 8.01 On November 16, 2016, the Company posted a presentation to its internet website located at www.nuvectramed.com that it is utilizing in connection with meetings with certain current and prospective investors, suppliers and customers of the Company (the “Presentation”). | nvtr20161115_8k.htm |
| 2016-11-09 | 8-K | 2016-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2016, Nuvectra Corporation issued a press release regarding its financial results for the quarter ended September 30, 2016. | nvtr20161108_8k.htm |
| 2016-08-10 | 8-K | 2016-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2016, Nuvectra Corporation issued a press release regarding its financial results for the quarter ended July 1, 2016. | nvtr20160809_8k.htm |
| 2016-08-01 | 8-K | 2016-08-01 | 8.01 Other Events | 8.01 On August 1, 2016, The Wall Street Transcipt posted a transcript of an interview with Nuvectra Corporation’s Chief Executive Officer, Mr. Scott F. Drees, to its internet website located at www.twst.com (the “Transcript”). | nvtr20160729_8k.htm |
| 2016-06-17 | 8-K | 2016-06-14 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | nvtr20160615_8k.htm |
| 2016-05-11 | 8-K | 2016-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2016, Nuvectra Corporation issued a press release regarding its financial results for the quarter ended April 1, 2016. | nvtr20160509_8k.htm |
| 2016-04-07 | 8-K | 2016-04-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | nvtr20160406_8k.htm | |
| 2016-03-30 | 8-K | 2016-03-30 | 7.01 Regulation FD Disclosure | 7.01 On March 30, 2016, the Company posted a presentation to its internet website located at www.nuvectramed.com that it is utilizing in connection with meetings with certain current and prospective investors, suppliers and customers of the Company (the “Presentation”). | nuve20160328_8k.htm |
| 2016-03-18 | 8-K | 2016-03-14 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.03 The information regarding the Loan Agreement included in Item 1.01 above is incorporated by reference into this Item 2.03. 3.02 The information regarding the Oxford Warrant and the Silicon Valley Warrant included in Item 1.01 above is incorporated by reference into this Item 3.02. 5.01 Immediately prior to the Spin-off, Nuvectra was a wholly-owned subsidiary of Greatbatch. 5.02 On March 14, 2016 prior to the Spin-off and in connection with the conversion of the Company into a Delaware corporation, each member of the Board of Managers of the Company resigned from all positions with the Company, and Greatbatch, as the sole stockholder of the Company, appointed eight directors to serve as the Nuvectra Board of Directors. 5.05 In connection with the Spin-off, the Board of Directors of Nuvectra adopted a Code of Ethics and a Code of Ethics for Chief Executive Officer and Senior Financial Officers. 8.01 On March 14, 2016, the Company, then a Delaware limited liability company named QiG Group, LLC, converted into Nuvectra Corporation, a Delaware corporation, by filing a certificate of conversion (the “Certificate of Conversion”), and a certificate of incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware. | nuve20160311_8k.htm |